July 2015 The Manager Australian Stock Exchange Company Announcements Office Level 4, Exchange Centre 20 Bridge Street Sydney NSW 2000 Dear Sir/Madam, Re: Results of 2015 Extraordinary General Meeting Resolution 1: That,

Australian Stock Exchange

Company Announcements

Level 4, Exchange Centre

Re: Results of 2015 Extraordinary General Meeting

pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, the Company ratifies the previous issue of 200,000,000 Warrants to the vendors of Immutep S.A. as part of the consideration to acquire 100% of the shares in Immutep S.A.

in accordance with the terms of the Share Sale Agreement between Prima BioMed Ltd and Immutep S.A. executed and announced on 2nd October 2014, on the terms and conditions set out in the Explanatory Notes.

This resolution was passed on a show of hands.

pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, the Company ratifies the previous issue of securities to Bergen Global Opportunity Fund, LP and/or its nominee(s) under the Share Purchase Agreement and Convertible

Security Agreement dated 2nd October 2014, namely 22,936,950 shares, on the terms and conditions set out in the Explanatory Notes.

This resolution was passed on a show of hands.

pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, the Company ratifies the previous issue of a total of 100,206,500 Shares to Ridgeback Capital Investments L.P. in accordance with the Subscription Agreement, on the

terms and conditions set out in the Explanatory Notes.

This resolution was passed on a show of hands.

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889

That, for the purposes of section 611 (item 7) of the Corporations Act and for all other purposes, the Company authorizes the Board to

issue to Ridgeback Capital Investments L.P. 8,475,995 Initial Warrants, 371,445,231 Coverage Warrants, 13,750,828 Convertible Notes, the Placement Shares and the issue of the ordinary shares upon any exercise of the Initial Warrants and Coverage

Warrants and conversion of any of the Convertible Notes, as further described in the Explanatory Notes.

passed on a show of hands.

(i) for the purposes

of Listing Rule 10.14 and for all other purposes, the Company approves and authorises the issue of 20,000,000 Performance Rights to subscribe for 20,000,000 fully paid ordinary shares in the Company to Mr Marc Voigt and/or his nominee within 1 month

after the date of this Extraordinary General Meeting, on the terms and conditions set out in the Explanatory Notes accompanying this notice; and

(ii) for the purposes of section 200E of the Corporations Act, approval be given in specified circumstances for the accelerated vesting of the

Performance Rights granted to Mr Voigt in the event of cessation of his employment as described in the Explanatory Memorandum.

This resolution was passed on a show of hands.

In accordance with Section 251AA of the Corporations Act, the following information is provided to the Australian Stock Exchange Limited for the proxy

votes received for each resolution passed by members of Prima BioMed Ltd at the Annual General Meeting held on 31 July 2015:

BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au ABN: 90 009 237 889